Kater, A. P., Harrup, R. A., Kipps, T. J., Eichhorst, B., Owen, C., Assouline, S. E., Lamanna, N., Robak, T., de la Serna, J., Jaeger, U., Cartron, G., Montillo, M., Mellink, C., Langerak, A. W., Chyla, B., Popovic, R., Jiang, Y., Millen, R., Lefebure, M., … Seymour, J. F. (2025). The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL. Blood Journal. https://doi.org/10.1182/blood.2024025525

D’Alessandro, A., Keele, G. R., Hay, A., Nemkov, T., Earley, E. J., Stephenson, D., Vincent, M., Deng, X., Stone, M., Dzieciatkowska, M., Hansen, K. C., Kleinman, S., Spitalnik, S. L., Roubinian, N., Norris, P. J., Busch, M. P., Page, G. P., Stockwell, B. R., Churchill, G. A., & Zimring, J. C. (2025). Ferroptosis regulates hemolysis in stored murine and human red blood cells. Blood, 145(7), 765–783. https://doi.org/10.1182/blood.2024026109

Sidana, S., Patel, K. K., Peres, L. C., Bansal, R., Kocoglu, M. H., Shune, L., Atrash, S., Smith, K., Midha, S., Ferreri, C. J., Dhakal, B., Dima, D., Costello, P., Wagner, C., Reshef, R., Hosoya, H., Mikkilineni, L., Atanackovic, D., Chhabra, S., … Hansen, D. K. (2024). Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma. Blood Journal. https://doi.org/10.1182/blood.2024025945

Brown, J. R., Eichhorst, B., Lamanna, N., O’Brien, S. M., Tam, C. S., Qiu, L., Jurczak, W., Zhou, K., Šimkovič, M., Mayer, J., Gillespie-Twardy, A., Ferrajoli, A., Ganly, P. S., Weinkove, R., Grosicki, S., Mital, A., Robak, T., Osterborg, A., Yimer, H. A., … Shadman, M. (2024). Sustained Benefit of Zanubrutinib vs Ibrutinib in Patients With R/R CLL/SLL: Final Comparative Analysis of ALPINE. Blood Journal. https://doi.org/10.1182/blood.2024024667

Chakraborty, R., Zanwar, S., Hegenbart, U., Bhutani, D., Gertz, M. A., Dispenzieri, A., Kumar, S. K., D’Souza, A., Patwari, A., Cowan, A. J., Chen, G., Milani, P., Palladini, G., Sanchorawala, V., Bodanapu, G., Schönland, S., Lentzsch, S., & Muchtar, E. (2024). Prognostic impact of cytogenetic abnormalities by FISH in AL amyloidosis with daratumumab-based frontline therapy. Blood Journal. https://doi.org/10.1182/blood.2024025899

Ocampo-Gonzalez, F. A., & Bhagat, G. (2024). KSHV/HHV-8-associated multicentric Castleman disease and nodal Kaposi sarcoma displaying a lymphangiectatic pattern. Blood, 144(5), 587–587. https://doi.org/10.1182/blood.2024024839

Nabeel, H., & Bhagat, G. (2024). Double-hit, double-expressor follicular lymphoma with plasmacytic differentiation. Blood, 144(3), 339–339. https://doi.org/10.1182/blood.2024023881

Dei Zotti, F., Qiu, A., D’Agati, V. D., Jagnarine, S., Kyritsis, E., Miller, A., Tredicine, M., Fliginger, D., Stone, E. F., Panch, S. R., & Hudson, K. E. (2024). Mitigation of Checkpoint Inhibitor-Induced Autoimmune Hemolytic Anemia through Modulation of Purinergic Signaling. Blood Journal. https://doi.org/10.1182/blood.2024024230

Akahoshi, Y., Spyrou, N., Weber, D., Aguayo-Hiraldo, P., Ayuk, F. A., Chanswangphuwana, C., Choe, H. K., Eder, M., Etra, A. M., Grupp, S. A., Hexner, E. O., Hogan, W. J., Kitko, C. L., Kraus, S., Al Malki, M. M., Merli, P., Qayed, M., Reshef, R., Schechter, T., … Ferrara, J. L. M. (2024). Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD. Blood Journal. https://doi.org/10.1182/blood.2024025106

Hassan, N., Yi, H., Malik, B., Gaspard-Boulinc, L., Samaraweera, S. E., Casolari, D. A., Seneviratne, J., Balachandran, A., Chew, T., Duly, A., Carter, D. R., Cheung, B. B., Norris, M., Haber, M., Kavallaris, M., Marshall, G. M., Zhang, X. D., Liu, T., Wang, J., … Wang, J. Y. (2024). Loss of the stress sensor GADD45A promotes stem cell activity and ferroptosis resistance in LGR4/HOXA9-dependent AML. Blood, 144(1), 84–98. https://doi.org/10.1182/blood.2024024072

Durot, E., Roos-Weil, D., Chauchet, A., Decroocq, J., Di Blasi, R., Gastinne, T., Bensaber, H., Cheminant, M., Jacquet, C., Guidez, S., Gros, F.-X., Bachy, E., Coste, A., Cony-Makhoul, P., Treon, S. P., Delmer, A., Reshef, R., Le Gouill, S., Castillo, J. J., & Houot, R. (2024). High efficacy of CD19 CAR T cells in patients with transformed Waldenström macroglobulinemia. Blood, 143(26), 2804–2807. https://doi.org/10.1182/blood.2024024452

Nemkov, T., Key, A., Stephenson, D., Earley, E. J., Keele, G. R., Hay, A., Amireault, P., Casimir, M., Dussiot, M., Dzieciatkowska, M., Reisz, J. A., Deng, X., Stone, M., Kleinman, S., Spitalnik, S. L., Hansen, K. C., Norris, P. J., Churchill, G. A., Busch, M. P., … D’Alessandro, A. (2024). Genetic regulation of carnitine metabolism controls lipid damage repair and aging RBC hemolysis in vivo and in vitro. Blood, 143(24), 2517–2533. https://doi.org/10.1182/blood.2024023983

Roeker, L. E., Woyach, J. A., Cheah, C. Y. Y., Coombs, C. C., Shah, N. N., Wierda, W. G., Patel, M. R., Lamanna, N., Tsai, D. E., Nair, B. C., Wang, C., Zhao, X., Liu, D., Radtke, D., Chapman, S., Marella, N., McNeely, S. C., & Brown, J. R. (2024). Fixed-Duration Pirtobrutinib plus Venetoclax with or without Rituximab in Relapsed/Refractory CLL: Phase 1b BRUIN Trial. Blood Journal. https://doi.org/10.1182/blood.2024024510

Ryu, J., Rämö, J. T., Jurgens, S. J., Niiranen, T., Sanna-Cherchi, S., Bauer, K. A., Haj, A., Choi, S. H., Palotie, A., Daly, M., Ellinor, P. T., & Bendapudi, P. K. (2024). Thrombosis risk in single- and double-heterozygous carriers of factor V Leiden and prothrombin G20210A in FinnGen and the UK Biobank. Blood, 143(23), 2425–2432. https://doi.org/10.1182/blood.2023023326

Nabeel, H., & Soderquist, C. R. (2024). Castleman disease with modest T-lymphoblastic proliferation. Blood, 143(19), 2012–2012. https://doi.org/10.1182/blood.2023023762

Dou, H., Wang, R., Tavallaie, M., Xiao, T., Olszewska, M., Papapetrou, E. P., Tall, A. R., & Wang, N. (2024). Hematopoietic and eosinophil-specific LNK(SH2B3) deficiency promotes eosinophilia and arterial thrombosis. Blood, 143(17), 1758–1772. https://doi.org/10.1182/blood.2023021055

Vadivel, C. K., Willerslev-Olsen, A., Namini, M. R. J., Zeng, Z., Yan, L., Danielsen, M., Gluud, M., Pallesen, E. M. H., Wojewoda, K., Osmancevic, A., Hedebo, S., Chang, Y.-T., Lindahl, L. M., Koralov, S. B., Geskin, L. J., Bates, S. E., Iversen, L., Litman, T., Bech, R., … Buus, T. B. (2024). Staphylococcus aureus induces drug resistance in cancer T cells in Sézary syndrome. Blood, 143(15), 1496–1512. https://doi.org/10.1182/blood.2023021671

Liu, W., Pircher, J., Schuermans, A., Ul Ain, Q., Zhang, Z., Honigberg, M. C., Yalcinkaya, M., Nakao, T., Pournamadri, A., Xiao, T., Hajebrahimi, M. A., Wasner, L., Stegner, D., Petzold, T., Natarajan, P., Massberg, S., Tall, A. R., Schulz, C., & Wang, N. (2024). Jak2 V617F clonal hematopoiesis promotes arterial thrombosis via platelet activation and cross talk. Blood, 143(15), 1539–1550. https://doi.org/10.1182/blood.2023022260

Mack, E. A., Dougher, M. C., Ginda, A. M., Cahill, C., Murter, M., Schell, K., Tanhehco, Y. C., Bhoj, V. G., Fesnak, A. D., Siegel, D. L., Kambayashi, T., Aqui, N. A., & O’Doherty, U. (2024). Red cell exchange for rapid leukoreduction in adults with hyperleukocytosis and leukostasis. Blood, 143(11), 1049–1054. https://doi.org/10.1182/blood.2023021895

Neelapu, S. S., Chavez, J. C., Sehgal, A. R., Epperla, N., Ulrickson, M., Bachy, E., Munshi, P. N., Casulo, C., Maloney, D. G., de Vos, S., Reshef, R., Leslie, L. A., Oluwole, O. O., Yakoub-Agha, I., Khanal, R., Rosenblatt, J., Korn, R., Peng, W., Lui, C., … Jacobson, C. A. (2024). Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5). Blood, 143(6), 496–506. https://doi.org/10.1182/blood.2023021243

Wang, Y., He, S., Calendo, G., Bui, T., Tian, Y., Lee, C. Y., Zhou, Y., Zhao, X., Abraham, C., Mo, W., Chen, M., Sanders-Braggs, R., Madzo, J., Issa, J.-P., Hexner, E. O., Wiest, D. L., Reshef, R., Xue, H.-H., & Zhang, Y. (2024). Tissue-infiltrating alloreactive T cells require Id3 to deflect PD-1–mediated immune suppression during GVHD. Blood, 143(2), 166–177. https://doi.org/10.1182/blood.2023021126

Leiding, J. W., Arnold, D. E., Parikh, S., Logan, B., Marsh, R. A., Griffith, L. M., Wu, R., Kidd, S., Mallhi, K., Chellapandian, D., Si Lim, S. J., Grunebaum, E., Falcone, E. L., Murguia-Favela, L., Grossman, D., Prasad, V. K., Heimall, J. R., Touzot, F., Burroughs, L. M., … Kang, E. M. (2023). Genotype, oxidase status, and preceding infection or autoinflammation do not affect allogeneic HCT outcomes for CGD. Blood, 142(24), 2105–2118. https://doi.org/10.1182/blood.2022019586

Stefanucci, L., Collins, J., Sims, M. C., Barrio-Hernandez, I., Sun, L., Burren, O. S., Perfetto, L., Bender, I., Callahan, T. J., Fleming, K., Guerrero, J. A., Hermjakob, H., Martin, M. J., Stephenson, J., Paneerselvam, K., Petrovski, S., Porras, P., Robinson, P. N., Wang, Q., … Vuckovic, D. (2023). The effects of pathogenic and likely pathogenic variants for inherited hemostasis disorders in 140 214 UK Biobank participants. Blood, 142(24), 2055–2068. https://doi.org/10.1182/blood.2023020118

Kanter, J., Thompson, A. A., Kwiatkowski, J. L., Parikh, S., Mapara, M., Rifkin-Zenenberg, S., Aygun, B., Kasow, K. A., Gupta, A. O., Zhang, L., Sheldon-Waniga, E., Gallagher, M., Gruppioni, K., Chawla, A., Elliot, H., Pierciey, F. J., Walters, M. C., & Tisdale, J. F. (2023). Efficacy, Safety, and Health-Related Quality of Life (HRQOL) in Patients with Sickle Cell Disease (SCD) Who Have Received Lovotibeglogene Autotemcel (Lovo-cel) Gene Therapy: Up to 60 Months of Follow-up. Blood, 142(Supplement 1), 1051–1051. https://doi.org/10.1182/blood-2023-174229

Brown, J. R., Eichhorst, B. F., Lamanna, N., O’Brien, S. M., Tam, C. S., Qiu, L., Kaźmierczak, M., Jurczak, W., Zhou, K., Simkovic, M., Mayer, J., Gillespie-Twardy, A. L., Ferrajoli, A., Ganly, P. S., Weinkove, R., Grosicki, S., Mital, A., Robak, T., Osterborg, A., … Shadman, M. (2023). Extended Follow-up of ALPINE Randomized Phase 3 Study Confirms Sustained Superior Progression-Free Survival of Zanubrutinib Versus Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL). Blood, 142(Supplement 1), 202–202. https://doi.org/10.1182/blood-2023-174289

Wang, E. S., Jonas, B. A., Watts, J. M., Jurcic, J., Ferrell, P. B., Dinner, S. N., Yang, J., Seiter, K., Mims, A., Donnellan, W. B., Blum, W., & Cortes, J. (2023). Factors Impacting Response to Olutasidenib in Patients with mIDH1 Acute Myeloid Leukemia. Blood, 142(Supplement 1), 6047–6047. https://doi.org/10.1182/blood-2023-187584

Gui, G., Dillon, L. W., Ravindra, N., Hegde, P. S., Andrew, G., Mukherjee, D., Wong, Z., Auletta, J. J., El Chaer, F., Chen, E. C., Chen, Y.-B., Corner, A., Devine, S. M., Iyer, S. G., Jimenez Jimenez, A. M., de Lima, M., Litzow, M. R., Kebriaei, P., Saber, W., … Hourigan, C. S. (2023). Measurable Residual IDH2 before Allogeneic Transplant for Acute Myeloid Leukemia. Blood, 142(Supplement 1), 424–424. https://doi.org/10.1182/blood-2023-186822

Cortes, J., Jurcic, J., Baer, M. R., Blum, W., Ferrell, P. B., Jonas, B. A., Lee, S., Mims, A., Patel, S. A., Schiller, G. J., Yang, J., & Watts, J. M. (2023). Olutasidenib for the Treatment of mIDH1 Acute Myeloid Leukemia in Patients Relapsed or Refractory to Hematopoietic Stem Cell Transplant, Prior mIDH1 Inhibitor, or Venetoclax. Blood, 142(Supplement 1), 2888–2888. https://doi.org/10.1182/blood-2023-187861

Daver, N., Zeidner, J. F., Yuda, J., Watts, J. M., Levis, M. J., Fukushima, K., Ikezoe, T., Ogawa, Y., Brandwein, J., Wang, E. S., Miyazaki, Y., Pardee, T., Hosono, N., Shima, T., Yokoyama, H., Asada, N., Jurcic, J., Cai, H., Watanabe, A., … Erba, H. P. (2023). Phase 1/2 First-in-Human Study of the Menin-MLL Inhibitor DSP-5336 in Patients with Relapsed or Refractory Acute Leukemia. Blood, 142(Supplement 1), 2911–2911. https://doi.org/10.1182/blood-2023-179252

Chakraborty, R., Bhutani, D., Mapara, M., Reshef, R., Maurer, M. S., Radhakrishnan, J., & Lentzsch, S. (2023). Reduced Early Mortality with Daratumumab-Based Frontline Therapy in Systemic AL Amyloidosis- Experience from the Columbia Amyloidosis Multidisciplinary Program. Blood, 142(Supplement 1), 4780–4780. https://doi.org/10.1182/blood-2023-187214

Diefenbach, C. S., Jegede, O., Ansell, S. M., Steidl, C., Natkunam, Y., Scott, D. W., Mehta-Shah, N., Amengual, J. E., Forlenza, C. J., Cole, P. D., Bartlett, N. L., David, K. A., Advani, R. H., Ambinder, R. F., Thomas, S., Ibrahimi, S., & Kahl, B. S. (2023). Results from an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412). Blood, 142(Supplement 1), 607–607. https://doi.org/10.1182/blood-2023-184531

Shadman, M., Tedeschi, A., Mohseninejad, L., Yang, K., Lamanna, N., Xu, S., Cohen, A. C., Challagulla, S., Xue, M., Williams, R., O’Brien, S. M., Brown, J. R., & Tam, C. S. (2023). Similar Efficacy of Ibrutinib Arms across ALPINE and ELEVATE-RR Trials in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison. Blood, 142(Supplement 1), 4655–4655. https://doi.org/10.1182/blood-2023-179222

Mohan, M., Shah, N., Luan, D., Monge, J., Forsberg, M., Bhatlapenumarthi, V., Balev, M., Patwari, A., Cheruvalath, H., Bhutani, D., Thanendrarajan, S., Dhakal, B., Zangari, M., Al Hadidi, S., Cooper, D. L., Lentzsch, S., van Rhee, F., D’Souza, A., Szabo, A., … Chakraborty, R. (2023). Teclistamab in Relapsed Refractory Multiple Myeloma: Multi-Institutional Real-World Study. Blood, 142(Supplement 1), 545–545. https://doi.org/10.1182/blood-2023-174875

Spyrou, N., Akahoshi, Y., Kowalyk, S., Morales, G., Beheshti, R., Aguayo-Hiraldo, P., Al Malki, M. M., Ayuk, F. A., Bader, P., Baez, J., Capellini, A., Choe, H., Defilipp, Z., Eder, M., Eng, G., Etra, A., Gleich, S., Grupp, S., Hexner, E., … Ferrara, J. L. M. (2023). A Day 14 Endpoint for Acute Gvhd Clinical Trials. Blood, 142(Supplement 1), 779–779. https://doi.org/10.1182/blood-2023-172955

Carvalho Poyraz, F., Ridha, M., Simonetto, M., Kumar, A., Hess, E., Magid-Bernstein, J., Connolly, E. S., Ghoshal, S., Agarwal, S., Park, S., Claassen, J., Hod, E. A., & Roh, D. (2023). ABO-Incompatible Platelet Transfusion Is Associated with Ischemic Lesions on Brain MRI in Patients with Intracerebral Hemorrhage. Blood, 142(Supplement 1), 1288–1288. https://doi.org/10.1182/blood-2023-186171

Gong, Z., Umoru, G., Monge, J., Shah, N., Mohyuddin, G. R., Radhakrishnan, S., Chakraborty, R., Schinke, C., D’Souza, A., & Mohan, M. (2023). Adverse Effects and Non-Relapse Mortality of BCMA-Directed Immunotherapies : An FDA Adverse Event Reporting System (FAERS) Database Study. Blood, 142(Supplement 1), 358–358. https://doi.org/10.1182/blood-2023-182695

Midha, S., Gurumurthi, A., Costello, P., Redd, R. A., Freeman, C. L. L., Castaneda, O., Gonzalez, R., Ionescu, F., Gaballa, M., Kalariya, N., Khouri, J., Dima, D., Kocoglu, M. H., Sborov, D., Wagner, C. B., Atrash, S., Voorhees, P. M., Hashmi, H., Davis, J. A., … Patel, K. K. (2023). Alternative Lymphodepletion Strategies Lead to Similar Response Rates and Toxicities in Standard-of-Care BCMA-Directed CAR-T Therapy in Relapsed Refractory Multiple Myeloma. Blood, 142(Supplement 1), 3499–3499. https://doi.org/10.1182/blood-2023-187565

Hijiya, N., Kapoor, S., Hoch, M., Descamps, L., Dhamal, V., & Torres Cardoso, A. P. (2023). ASC4KIDS: A Multicenter, Open-Label, Phase Ib/II Study to Determine the Dose and Safety of Asciminib in Pediatric Patients with Chronic Myeloid Leukemia in the Chronic Phase. Blood, 142(Supplement 1), 6387–6387. https://doi.org/10.1182/blood-2023-185535

Hanna, R., Frangoul, H., McKinney, C., Pineiro, L., Mapara, M., Dalal, J., Chang, K.-H., Jaskolka, M., Kim, K., Farrington, D. L., Wally, M., Mei, B., Lawal, A., Afonja, O. O., & Walters, M. C. (2023). AsCas12a Gene Editing of HBG1/2 Promoters with EDIT-301 Results in Rapid and Sustained Normalization of Hemoglobin and Increased Fetal Hemoglobin in Patients with Severe Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia. Blood, 142(Supplement 1), 4996–4996. https://doi.org/10.1182/blood-2023-187397

Roh, D., Davis, J. M., Lee, T., Mitchell, P. M., Bookwalter, D., Stone, E., Karafin, M. S., Cushing, M. M., Spencer, B. R., Bruhn, R., Gottschall, J. L., Mast, A. E., Cable, R. G., Kleinman, S., & Hod, E. A. (2023). Assessing Donor and Platelet Transfusion Characteristics on Intracranial Hemorrhage Outcomes. Blood, 142(Supplement 1), 4038–4038. https://doi.org/10.1182/blood-2023-180236

Chakraborty, R., Cliff, E. R. S., & Kishtagari, A. (2023). Assessing the Impact of Blood Cancer Talks, a Novel ‘how I Treat’ Style Podcast on Hematologic Malignancies: A Survey-Based Analysis. Blood, 142(Supplement 1), 7270–7270. https://doi.org/10.1182/blood-2023-184594

Neelapu, S. S., Chavez, J. C., Sehgal, A. R., Epperla, N., Ulrickson, M. L., Bachy, E., Munshi, P. N., Casulo, C., Maloney, D. G., de Vos, S., Reshef, R., Leslie, L. A., Oluwole, O. O., Yakoub-Agha, I., Khanal, R., Rosenblatt, J. D., Peng, W., Lui, C., Wulff, J., … Jacobson, C. A. (2023). Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 4-Year Follow-up from the Phase 2 ZUMA-5 Trial. Blood, 142(Supplement 1), 4868–4868. https://doi.org/10.1182/blood-2023-174914

De Simone, P., Bal, E., Holmes, A., Hilton, L., Basso, K., Soni, R. K., Morin, R., Dalla-Favera, R., & Pasqualucci, L. (2023). BTG2 Super-Enhancer Mutations Disrupt TFAP4 Binding and Deregulate BTG2 Expression in Diffuse Large B-Cell Lymphoma. Blood, 142(Supplement 1), 523–523. https://doi.org/10.1182/blood-2023-190230

Durot, E., Roos-Weil, D., Chauchet, A., Decroocq, J., Di Blasi, R., Gastinne, T., Bensader, H., Cheminant, M., Jacquet, C., Guidez, S., Gros, F.-X., Bachy, E., Cony-Makhoul, P., Treon, S. P., Delmer, A. J., Reshef, R., Le Gouill, S., Castillo, J. J., & Houot, R. (2023). CD19-Targeting CAR T-Cell Therapy in Transformed Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: A Descar-T and US Collaborative Study. Blood, 142(Supplement 1), 616–616. https://doi.org/10.1182/blood-2023-173988

Wang, X. K., Uzuni, A., Belay, K., Harle, D. W., Gordillo, C. A., Macedo, R. J., Chakrabarti, S., Shi, L., Pressler, M., Fuller, J., Azizi, E., & Reshef, R. (2023). Characteristics of Alloreactive T-Cell Clones That Predict Early Development of Acute GvHD Following Allogeneic HCT. Blood, 142(Supplement 1), 2042–2042. https://doi.org/10.1182/blood-2023-187932

Fu, J., Li, S., MA, H., Brown, L. M., Mapara, M., & Lentzsch, S. (2023). Checkpoint Inhibitor PD-1H/VISTA Affects Myeloma Bone Disease By Osteoclast Cytoskeleton Remodeling. Blood, 142(Supplement 1), 6610–6610. https://doi.org/10.1182/blood-2023-189820

Piorczynski, T. B., Ryu, Y. K., Pazos, M., Huang, W., Tolu, S. S., Estrella, B., & Amengual, J. E. (2023). Combination Epigenetic Therapy Using YF2, a First-in-Class Histone Acetyltransferase Activator, Restores Immunogenicity in Diffuse Large B-Cell Lymphoma. Blood, 142(Supplement 1), 4391–4391. https://doi.org/10.1182/blood-2023-179271

Garcia-Manero, G., Odenike, O., Fleming, S., Roboz, G. J., Jacoby, M., Cunningham, I., Kreuzer, K.-A., Enjeti, A. K., Baer, M. R., Cook, R., Jurcic, J., Ku, G., Zhou, Y., Hoffman, D., Potluri, J., & Garcia, J. S. (2023). Combination of Venetoclax and Azacitidine in Patients with Treatment-Naive, High-Risk Myelodysplastic Syndromes with Responses Leading to Stem Cell Transplantation. Blood, 142(Supplement 1), 1868–1868. https://doi.org/10.1182/blood-2023-187102

Topping, R. P., Quill, T. A., Lamanna, N., & Sharman, J. P. (2023). Determining Clinical Practice Gaps for HCPs in Treating CLL Using CME-Based Surveys. Blood, 142(Supplement 1), 3716–3716. https://doi.org/10.1182/blood-2023-190329

Fahmy, L. M., Yang, H. R., Zhou, M., Beylergil, V., Schreidah, C. M., Bilgrami, Z., Kwinta, B. D., Schwartz, L., Fojo, A. T., Bates, S. E., & Geskin, L. J. (2023). Dynamic Changes in Lymph Node Size and Skin Scoring Predict Response to Treatment in CTCL: An Interim Analysis. Blood, 142(Supplement 1), 4443–4443. https://doi.org/10.1182/blood-2023-189493